Genworth's Careful Calm: Leadership Transition, LTC Claims Creep, and a Patient Capital Return Story
A steady quarter with a lurking claims-risk caveat and a disciplined capital plan that rewards patience.
GNW · Earnings Call · 2026-08-06
A Quiet Quarter with a Loud Caveat
The second quarter was arguably the calmest Genworth has sounded in years—even as the company operates under an interim CEO. Following Tom McInerney's medical leave, CFO Jerome Upton has stepped into the top role, and the leadership team has leaned into continuity. “Genworth has a deep and experienced leadership team that has been actively engaged with Tom and our board in the development of our strategy.” — Jerome Thomas Upton, CEO · 2026-08-06 That steadiness is reflected in the numbers: Enact delivered $143 million of adjusted operating income to Genworth, and capital returns from the mortgage insurer support the holding company's share repurchase machine. But beneath the surface, the leadership team is managing a slow-burn issue in the legacy long-term care closed block that deserves investor attention. The most consequential data point on the call was not the headline earnings, but the closed block ages—and the actuarial variance that comes with it. Management flagged that A-to-E losses in the first half are running above the level implied by their full-year expectation of roughly $300 million. “Our A to E loss experience in the first half of 2026 has trended above the level implied by our full year expectation of approximately $300 million. While results can vary quarter to quarter, if these trends continue, the full year A to E losses could be higher than that level.” — Jerome Thomas Upton, CEO · 2026-08-06 This is a notable acknowledgement, even as management stresses that these GAAP fluctuations do not affect cash flows or economic value. For a company that has long argued its closed block is self-sustaining, the creeping claims experience is a reminder that the multiyear rate action plan (MYRAP) is working, but the tail risk is not fully tamed. The closed block generated an adjusted operating loss of $110 million, driven by a liability remeasurement loss tied to A-to-E variances, primarily in LTC. It is a stark contrast to the prior-year narrative when statutory income was boosted by legal settlements and COVID-related mortality. As CEO McInerney said back in November “For the legacy business, it's a runoff, it's a long runoff because probably of the 1 million policyholders we have individual and group that runoff will be 30 years or more.” — Thomas McInerney, CEO · 2025-11-06 The key question is whether the current A-to-E trend is a blip or the beginning of a more persistent pressure point.CareScout: Growth Ahead of Schedule, Revenue in Line
The strategic bright spot remains CareScout, and the company is spending to scale it. The CareScout network now includes over 1,100 home care locations and is adding senior living communities at a fast clip. The company has also doubled the number of local advisers to 26 states. Matches—the top-line KPI for the services business—roughly doubled year-over-year in the first half. “We facilitated approximately 1.45 thousand matches between care seekers and providers in the second quarter. Bringing total matches for the first half of the year to approximately 2.95 thousand over double the number of matches achieved in the first half of 2025.” — Jerome Thomas Upton, CEO · 2026-08-06 However, management conceded that current match volumes are pacing below what is needed to hit the full-year target of ~7,500, while still reaffirming $25 million of revenue and $50–55 million of investment. This is a classic growth-stage tension: early traction is strong, but the linearity of the ramp is uncertain. The company is also launching a worksite version of its CareAssurance product in at least 34 states, which opens a new distribution channel and extends the CareScout brand beyond the legacy policyholder base.Capital Return Discipline
On the capital side, Genworth continues to execute the playbook it has run for years: return cash from Enact, buy back shares when the price is below intrinsic value, and use the AXA litigation proceeds opportunistically. The company bought back $62 million of shares at an average price of $8.74 per share in the quarter, and raised full-year buyback guidance to $225–$250 million. “We repurchased $62 million of shares at an average price of $8.74 per share and an additional $4 million in July. We also retired $10 million of principal debt in the quarter at a discount.” — Jerome Thomas Upton, CEO · 2026-08-06 Since the program’s inception in 2022, Genworth has repurchased approximately $922 million worth of shares at an average price of $6.48 per share—a level well below the current price, which should create meaningful per-share accretion over time. The potential AXA recovery remains the big optionality. The appeal hearing occurred in July, and management is awaiting a decision within 3–6 months. On the call, general counsel Gregory Karawan offered only the most cautious of outlooks.The company remains consistent that any proceeds would be deployed against the same priorities—CareScout, buybacks, and debt reduction—and not factored into the base plan.The only color commentary I can give you is that I think Axis lawyers did an excellent job. But having been in this business for 40, almost 40 years, I know 1 thing for certain, and that is litigation is inherently uncertain.